Source link : https://www.newshealth.biz/health-news/new-drug-class-for-prurigo-nodularis-moving-forward/
AMSTERDAM — Prurigo nodularis (PN), an itchy, highly symptomatic disease that can cause severe impairments in quality of life, may gain a third therapy if promising data on povorcitinib presented at the European Academy of Dermatology and Venereology (EADV) 2024 Congress are further validated. “We now have a pipeline of clinical studies in PN. Who […]
Author : News Health
Publish date : 2024-10-07 09:49:10
Copyright for syndicated content belongs to the linked Source.
inHealth